Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DURECT Corporation
  6. Company
    DRRX   US2666051048

DURECT CORPORATION

(DRRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo DURECT Corporation
DURECT Corporation is a biopharmaceutical company focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. DURÔÇĹ928 is a candidate in its Epigenetic Regulator Program. Injectable DUR-928 is under testing in a Phase II clinical trial and oral DUR-928 is under testing in a Phase I clinical trial. The chronic toxicity of DUR-928 was further assessed in a 6-month oral study in rats and in a 9-month oral study in dogs. POSIMIR enabling continuous sustained delivery of bupivacaine, a non-opioid local analgesic, over 3 days in adults to control post-surgical pain of patients.

Number of employees : 81 people.
Sales per Business
20192020Delta
Pharmaceutical Products29.56100%30.11100% +1.85%
USD in Million
Sales per region
20192020Delta
United States22.8377.2%26.8989.3% +17.83%
Europe3.1310.6%1.394.6% -55.75%
Japan1.485%1.173.9% -20.46%
Others2.137.2%0.662.2% -69.17%
USD in Million
Managers
Name Title Age Since
James E. Brown, Dr. President, Chief Executive Officer & Director 63 1998
Michael H. Arenberg Chief Financial Officer & Secretary 50 -
Wei Qi Lin, Dr. Executive Vice President-Research & Development - -
David J. Ellis, Dr. Vice President-Clinical Development - 2015
Norman L. Sussman, Dr. Chief Medical Officer 67 2020
Judy R. Joice Senior VP-Operations & Corporate Quality Assurance 63 2014
David R. Hoffmann Chairman 75 2018
Terrence F. Blaschke, Dr. Independent Director 77 2006
Simon X. Benito Independent Director 75 2005
Judith J. Robertson Independent Director 60 2019
Members of the board
Name Title Age Since
David R. Hoffmann Chairman 75 2018
James E. Brown, Dr. President, Chief Executive Officer & Director 63 1998
Terrence F. Blaschke, Dr. Independent Director 77 2006
Simon X. Benito Independent Director 75 2005
Judith J. Robertson Independent Director 60 2019
Gail M. Farfel, Dr. Independent Director 56 2019
Gail J. Maderis Director 62 2021
Mohammad Magdy Mohamed Azab, Dr. Director 64 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 227,496,180 224,239,417 98.6% 0 0.0% 98.6%
Shareholders
NameEquities%
First Eagle Investment Management LLC 26,476,546 11.6%
Bleichroeder LP 26,414,656 11.6%
Lion Point Capital LP 15,308,569 6.73%
The Vanguard Group, Inc. 10,757,120 4.73%
Broadfin Capital LLC 8,506,229 3.74%
Ingalls & Snyder LLC 7,417,805 3.26%
Camber Capital Management LP 6,000,000 2.64%
BlackRock Fund Advisors 5,061,090 2.22%
VHCP Management LLC 4,444,444 1.95%
SSgA Funds Management, Inc. 4,343,280 1.91%
Company contact information
DURECT Corp.
10260 Bubb Road
Cupertino, CA 95014-4166

Phone : +1.408.777.1417
Fax : +1.408.777.3577
Web : http://www.durect.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of DURECT Corporation
Sector Bio Therapeutic Drugs